Isn't it better if the the interim results get pushed back farther? My impression is that if the trial goes well, then survival should be high, thus making it harder to hit the necessary deaths to report interim.
Not necessary, We have seen many of them with negative delayed results,
just to name a few, PARD, GNVC, ONTY and CLSN. VICL may be on the top,
with its trial still waiting for OS, it is already close 1.5 years later, I see it fails, the
only reason is if the drug is that good, the OS advantage will make DMC stop the
trial long time ago.
Certainly that would be a logical explanation for taking longer to reach the prerequisite # of deaths . But it's also possible that the patients receiving standard of care are living longer than was originally expected. It is best to wait for results,